13F Holdings
中文EN

SNY Sanofi IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1121404 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY6.2%
TTM net income YoY40.5%
TTM EPS YoY43.8%
Revenue 3-yr CAGR5.0%
Net income 3-yr CAGR-2.3%

Margins

Gross margin77.2%
Operating margin14.5%
Net margin17.9%
FCF margin—
EBITDA margin—

Returns

ROE10.5%
ROA6.0%
ROIC (approx.)6.0%
Asset turnover0.34x

Leverage & solvency

Liabilities / assets43.4%
Debt / equity0.26x
Current ratio1.09x
Interest coverage11.27x

Cash quality & payout

Operating cash flow / net income1.38x
Accruals ratio-2.3%
Payout ratio61.1%
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue43.63B41.08B37.82B37.65B37.76B
Cost of revenue13.05B13.21B12.63B11.88B12.26B
Gross profit33.67B31.08B28.99B28.68B26.92B
R&D expense7.84B7.39B6.51B6.50B5.69B
SG&A expense9.54B9.18B8.93B8.74B9.55B
Operating income6.34B7.25B6.96B10.16B8.13B
Interest expense563.00M1.07B1.29B430.00M368.00M
Income tax1.04B1.20B1.02B1.91B1.56B
Net income7.81B5.56B5.40B8.37B6.22B
EPS (basic)6.404.444.316.69—
EPS (diluted)6.374.434.306.66—
Weighted avg. shares (diluted)1.23B1.26B1.26B1.26B1.26B
Balance sheet
Cash & equivalents7.66B7.44B8.71B12.74B10.10B
Receivables8.41B7.68B8.43B8.42B7.57B
Inventory10.21B9.43B9.67B8.96B8.71B
Current assets30.95B42.59B30.67B34.11B—
PP&E, netmay include right-of-use assets (IFRS)10.05B10.09B10.16B9.87B10.03B
Goodwill41.30B43.38B49.40B49.89B48.06B
Intangibles26.26B22.63B24.32B21.64B21.41B
Total assets126.81B132.80B126.46B126.72B120.24B
Current liabilities28.34B29.16B24.21B23.97B—
Short-term debt4.34B4.21B2.04B4.17B3.18B
Long-term debt14.25B11.79B14.35B14.86B17.12B
Total debt18.59B16.00B16.39B19.03B20.31B
Total liabilities55.09B54.94B52.11B51.57B51.21B
Shareholders' equity71.38B77.51B74.04B74.78B68.68B
Net debt10.93B8.56B7.68B6.29B10.21B
Cash flow statement
Operating cash flow10.75B9.08B10.26B10.53B10.52B
Investing cash flow-2.45B-4.41B-6.20B-2.08B-7.30B
Financing cash flow-8.21B-5.76B-8.05B-5.82B-7.06B
Stock-based compensation313.00M278.00M260.00M234.00M244.00M
Dividends paid4.77B4.70B4.45B4.17B4.01B
Share buybacks5.03B302.00M593.00M497.00M382.00M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.